AbbVie Inc. stock gains on Apogee deal and reaffirmed 2026 guidance

{
  "signal_id": "0676dd30-3675-84e1-61da-c3dd07af2754",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-09-04T16:01:36+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/abbvie-inc-stock-gains-on-apogee-deal-and-reaffirmed-2026-guidance/70055493",
    "title": "AbbVie Inc. stock gains on Apogee deal and reaffirmed 2026 guidance - AD HOC NEWS",
    "excerpt": "AbbVie Inc. (ISIN US00287Y1091) stock is trading around USD 260 as of September 4, 2026, after the company completed its USD 10.9 billion acquisition of Apogee Therapeutics and reaffirmed robust full-year 2026 earnings guidance in the range of USD 13.87 to USD 14.07 per share. According to a report on Allsci dated September 4, 2026 , AbbVie closed its purchase of Apogee Therapeutics on September 3, 2026, paying USD 135.11 per Apogee share in cash for a total equity value of approximately USD 10.9 billion. The deal brings Apogee's clinical-stage immunology pipeline into AbbVie, including candidates for atopic dermatitis, asthma and chronic obstructive pulmonary disease, complementing blockbuster drugs Skyrizi and Rinvoq that already anchor AbbVie's immunology franchise. A separate US market wrap from HDFC Sky's US corporate summary notes that Apogee shareholders received USD 135.11 per share and that Apogee common stock ceased trading on Nasdaq before the market opened once the transaction closed. Beyond the pipeline boost, the equity story remains anchored in AbbVie's current earnings power. As summarized by MarketBeat's guidance update dated September 3, 2026 , AbbVie reaffirmed its adjusted EPS guidance for fiscal year 2026 at USD 13.87 to USD 14.07, broadly in line with the analyst consensus of about USD 14.02 per share. For the third quarter of 2026, AbbVie guided to...",
    "summary": "AbbVie reaffirmed its adjusted EPS guidance for fiscal year 2026 at USD 13.87 to USD 14.07.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2700583_1920_1080.webp",
    "confidence": 0.9,
    "published_at": "2026-09-04T16:01:36Z",
    "article_sentence": "As summarized by MarketBeat's guidance update dated September 3, 2026 , AbbVie reaffirmed its adjusted EPS guidance for fiscal year 2026 at USD 13.87 to USD 14.07, broadly in line with the analyst consensus of about USD 14.02 per share."
  }
}

curl https://signals.autobound.ai/v1/signals/0676dd30-3675-84e1-61da-c3dd07af2754 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'